Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aviron -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (611)	7/27/2001 2:12:09 PM
From: tuck	Respond to of 645

FWIW, from Briefing.com: >>8:55AM Aviron (AVIR) 40.80: SG Cowen reports that the first day of FDA FluMist BLA review went well. Believes likely outcome is an approval for healthy children and adults ages 1-64. << Cheers, Tuck, whose straddle will do better if approval granted

To: Biomaven who wrote (611)	7/27/2001 2:57:30 PM
From: tuck	Read Replies (1) \| Respond to of 645

Peter, SG Cowen's feelings not worth much. That comment about the safety review not being done was the red flag: rejected. >>GAITHERSBURG, Md., July 27 (Reuters) - A U.S. advisory panel on Friday rejected Aviron's (NasdaqNM:AVIR - news) FluMist, a nasal spray vaccine, for preventing influenza in healthy children and adults. The Food and Drug Administration advisory committee said FluMist was effective for preventing the flu in healthy children and adults, but voted 10 to four that it did not have enough information to say the vaccine was safe. The final decision on approving FluMist rests with the FDA. The agency usually follows its panel's advice. If it were to gain approval, American Home Products Corp. (NYSE:AHP - news) would co-market FluMist.<< snip Cheers, Tuck